No Detail Found!

Role of Ruxolitinib in Steroid-Refractory Graft versus Host Disease in Patients Undergoing Allogeneic Stem Cell Transplant

Author(s)
Hammad Javed Department of Clinical Hematology, Armed Forces Bone Marrow Transplant Center (AFBMTC), Rawalpindi, Pakistan
Qamarunnisa Chaudhry Department of Clinical Hematology, Armed Forces Bone Marrow Transplant Center (AFBMTC), Rawalpindi, Pakistan
Nighat Shahbaz Department of Clinical Hematology, Armed Forces Bone Marrow Transplant Center (AFBMTC), Rawalpindi, Pakistan
Mehreen Ali Khan Department of Clinical Hematology, Armed Forces Bone Marrow Transplant Center (AFBMTC), Rawalpindi, Pakistan
Raheel Iftikhar Department of Clinical Hematology, Armed Forces Bone Marrow Transplant Center (AFBMTC), Rawalpindi, Pakistan
Muhammad Yousaf Department of Clinical Hematology, Armed Forces Bone Marrow Transplant Center (AFBMTC), Rawalpindi, Pakistan
Abstract
The objective of this study was to evaluate the role of Ruxolitinib in steroid-refractory graft versus host disease. This retrospective descriptive study was conducted from January 2018 to December 2021. A total of 157 patients underwent allogeneic stem cell transplants during the study period. Of these, 20 patients having steroid-refractory GVHD treated with Ruxolitinib were selected for the study. The primary endpoint was the overall response rate to Ruxolitinib measured at 4 weeks and 24 weeks for acute and chronic GVHD, respectively. The secondary endpoints were overall survival and failure-free survival.Of these 20 patients, 7 (35%) had acute GVHD, and 13 (65%) had chronic GVHD. Of acute GVHD, 2 (10%) had grade II, 4 (20%) had grade III, and 1 (5%) had grade IV acute GVHD. Of 13 patients with chronic GVHD, 7 (35%) had moderate and 6 (30%) had severe chronic GVHD. In steroid-refractory acute GVHD, the overall response rate to Ruxolitinib was 85.7%, and in chronic GVHD, it was 84.6%. The failure-free survival was 80% and overall survival was 85%.Adverse events of any grade occurred in 16 (80%) patients with grade III/IV adverse events in 4 (20%) patients onlyT.he study showed that Ruxolitinib is a safe and e ective second-line therapy for acute and chronic steroid-refractory GVHD.
Publication Details
Page(s) 1225-1227
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 32, Issue: 9, Year: 2022

Request the full text from PASTIC

Keywords
Ruxolitinib, Allogeneic stem cell transplant, GVHD
0

Citations

0

Downloads

52

Views